CORESTEMCHEMON Inc. (KOSDAQ:166480)
1,754.00
-27.00 (-1.52%)
At close: Jul 21, 2026
CORESTEMCHEMON Revenue
CORESTEMCHEMON had revenue of 4.35B KRW in the quarter ending March 31, 2026, a decrease of -28.96%. This brings the company's revenue in the last twelve months to 18.39B, down -30.58% year-over-year. In the year 2025, CORESTEMCHEMON had annual revenue of 20.16B, down -29.91%.
Revenue (ttm)
18.39B
Revenue Growth
-30.58%
P/S Ratio
4.23
Revenue / Employee
510.75M
Employees
36
Market Cap
77.81B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.16B | -8.60B | -29.91% |
| Dec 31, 2024 | 28.76B | -4.89B | -14.54% |
| Dec 31, 2023 | 33.66B | -12.22B | -26.64% |
| Dec 31, 2022 | 45.88B | 15.64B | 51.71% |
| Dec 31, 2021 | 30.24B | 3.88B | 14.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 128.76B |
| KoBioLabs | 71.21B |
| Cell Biotech | 56.49B |
| Choong Ang Vaccine Laboratory | 39.19B |
| BIO-FD&C | 18.85B |
| PanGen Biotech | 13.71B |
| QuadMedicine | 9.78B |
| EyeGene | 4.02B |